Skip to main content

Advertisement

SpringerLink
Log in

Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

A critical element in improving the potency of cancer vaccines, especially pure protein or peptide antigens, is to develop procedures that can strongly but safely increase their ability to induce immune responses. Here, we describe that encapsulation of a pure protein antigen and interleukin-2 (IL-2) together into liposomes significantly improves immune responses and tumor protection. Groups of C57Bl/6 mice were immunized weekly ×4 with –0.1 mg of ovalbumin (OVA) injected subcutaneously in PBS or encapsulated in liposomes with or without human recombinant IL-2. Control groups included mice immunized to irradiated E.G7-OVA cells (that express ovalbumin), or to PBS. Sera were collected and pooled by immunization group at baseline and at weeks 2 and 4 to measure antibody responses to OVA by ELISA. Splenocytes obtained at week 4 were tested for anti-OVA cellular responses by ELISPOT. Mice were then challenged to a lethal dose of E.G7-OVA cells to measure tumor-protective immunity. IL-2 liposomes caused no detectable toxicity. Antibody, CD8+ T cell, and tumor-protective immune responses were markedly enhanced in mice immunized to OVA + IL-2 in liposomes compared to mice immunized to OVA, either alone or encapsulated into liposomes without IL-2. These results indicate that IL-2 liposomes enhance antibody, cellular, and tumor-protective immune responses to immunization with a soluble protein. This may provide a simple, safe, and effective way to enhance the immunogenicity of vaccines that consist of pure protein antigens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Alam A, Imliwati L, Rapthap C, Singh V (2001) Liposome encapsulated tumor-associated antigens elicited humoral and cellular immune responses in mice bearing tumor. Indian J Exp Biol 39:201–208

    PubMed  CAS  Google Scholar 

  2. Akiyama Y, Maruyama K, Nara N, Mochizuki T, Yamamoto A, Yamazaki N, Kawashima I, Nukaya I, Takesako K, Yamaguchi K (2004) Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail. Anticancer Res 24:571–577

    PubMed  CAS  Google Scholar 

  3. Anderson PM, Katsanis E, Spencer SF, Hasz D, Ochoa AC, Bostrom B (1992) Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration. J Immunother 12:19–36

    Article  PubMed  CAS  Google Scholar 

  4. Anderson PM, Hanson DC, Hasz DE, Halet MR, Blazar BR, Ochoa AC (1994) Cytokines in liposomes: preliminary studies with IL-2, IL-6, GM-CSF and interferon-gamma. Cytokine 6:92–101

    Article  PubMed  CAS  Google Scholar 

  5. Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, Ritter E, Santiago D, Ferrara CA, Matsuo M, Selvakumar A, Dupont B, Chen YT, Hoffman EW, Ritter G, Old LJ, Gnjatic S (2004) Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 172:3289–3296

    PubMed  CAS  Google Scholar 

  6. Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC (2004) Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 113:1515–1525

    Article  PubMed  CAS  Google Scholar 

  7. Blattman JN, Greenberg PD (2004) Cancer immunotherapy: a treatment for the masses. Science 305:200–205

    Article  PubMed  CAS  Google Scholar 

  8. Brinkman JA, Fausch SC, Weber JS, Kast WM (2004) Peptide-based vaccines for cancer immunotherapy. Exp Opin Biol Ther 4:181–198

    Article  CAS  Google Scholar 

  9. Bystryn J-C, Oratz R, Roses D, Harris M, Henn M, Lew R (1992) Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 69:1157–1164

    Article  PubMed  CAS  Google Scholar 

  10. Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, Shapiro RL, Harris MN, Roses DF (2001) Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 7:1882–1887

    PubMed  CAS  Google Scholar 

  11. Bystryn JC (2002) Vaccines for melanoma. Dermatol Clin 20:717–725

    Article  PubMed  CAS  Google Scholar 

  12. Davila E, Kennedy R, Celis E (2003) Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 63:3281–3288

    PubMed  CAS  Google Scholar 

  13. Dermime S, Gilham DE, Shaw DM, Davidson EJ, Meziane el-K, Armstrong A, Hawkins RE, Stern PL (2004) Vaccine and antibody-directed T cell tumour immunotherapy. Biochim Biophys Acta 1704:11–35

    PubMed  CAS  Google Scholar 

  14. Donoline JH, Rosenberg SA (1983) The fate of interleukin-2 after in vivo administration. J Immunol 130:2203–2208

    PubMed  Google Scholar 

  15. Gershman N, Johnston D, Bystryn J-C (1994) Potentiation of B16 melanoma vaccine immunogenicity by IL-2 liposomes. Vaccine Res 3:83–92

    CAS  Google Scholar 

  16. Hanson HL, Kang SS, Norian LA, Matsui K, O’Mara LA, Allen PM (2004) CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors. J Immunol 172:4215–4224

    PubMed  CAS  Google Scholar 

  17. Hsueh EC, Morton DL (2003) Antigen-based immunotherapy of melanoma: canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol 13:401–407

    Article  PubMed  CAS  Google Scholar 

  18. Kast WM, Levitsky H, Marincola FM (2004) Synopsis of the 6th Walker’s cay colloquium on cancer vaccines and immunotherapy. J Transl Med 2(1):20

    Article  PubMed  Google Scholar 

  19. Kohlgraf KG, Gawron AJ, Higashi M, Meza JL, Burdick MD, Kitajima S, Kelly DL, Caffrey TC, Hollingsworth MA (2003) Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res 63:5011–5020

    PubMed  CAS  Google Scholar 

  20. Koppenhagen FJ, Kupcu Z, Wallner G, Crommelin DJ, Wagner E, Storm G, Kircheis R (1998) Sustained cytokine delivery for anticancer vaccination: liposomes as alternative for gene-transfected tumor cells. Clin Cancer Res 8:1881–1886

    Google Scholar 

  21. Krup OC, Kroll I, Bose G, Falkenberg FW (1999) Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation. J Immunother 22:525–538

    Article  PubMed  CAS  Google Scholar 

  22. Lewis JJ (2004) Therapeutic cancer vaccines: using unique antigens. Proc Natl Acad Sci USA 101(Suppl2):14653–14656 Epub

    Google Scholar 

  23. Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G et al (1994) Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036–1044

    PubMed  CAS  Google Scholar 

  24. Lo-Man R, Vichier-Guerre S, Perraut R, Deriaud E, Huteau V, BenMohamed L, Diop OM, Livingston PO, Bay S, Leclerc C (2004) A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates. Cancer Res 64:4987–4994

    Article  PubMed  CAS  Google Scholar 

  25. Lotem M, Shiloni E, Pappo I, Drize O, Hamburger T, Weitzen R, Isacson R, Kaduri L, Merims S, Frankenburg S, Peretz T (2004) Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer 90:773–780

    Article  PubMed  CAS  Google Scholar 

  26. Lu J, Higashimoto Y, Appella E, Celis E (2004) Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol 172:4575–4582

    PubMed  CAS  Google Scholar 

  27. Marincola FM, Ferrone S (2003) Immunotherapy of melanoma: the good news, the bad ones and what to do next. Sem Cancer Biol 13:387–389

    Article  Google Scholar 

  28. Miller K, Abeles G, Oratz R, Zeleniuch-Jacquotte A, Cui J, Roses DF, Harris M, Bystryn J-C (1995) Improved survival of melanoma patients with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 75:495–502

    Article  PubMed  CAS  Google Scholar 

  29. Moore MW, Carbone FR, Bevan MJ (1988) Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54:777–785

    Article  PubMed  CAS  Google Scholar 

  30. Neville ME, Boni LT, Pflug LE, Popescu MC, Robb RJ (2000) Biopharmaceutics of liposomal interleukin 2, oncolipin. Cytokine 12:1691–1701

    Article  PubMed  CAS  Google Scholar 

  31. Nguyen CL, Salem ML, Rubinstein MP, Demcheva M, Vournakis JN, Cole DJ, Gillanders WE (2003) Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2). Vaccine 21:2318–2328

    Article  PubMed  CAS  Google Scholar 

  32. Phan GQ, Touloukian CE, Yang JC, Restifo NP, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2003) Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother 6:349–356

    Article  Google Scholar 

  33. Platsoucas CD, Fincke JE, Pappas J, Jung WJ, Heckel M, Schwarting R, Magira E, Monos D, Freedman RS (2003) Immune responses to human tumors: development of tumor vaccines. Anticancer Res 23:1969–1996

    PubMed  CAS  Google Scholar 

  34. Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn J-C (1998) HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan A/MART-1, gp100, tyrosinase, MC1R and TRP-2 in vaccine-treated melanoma patients. J Immunol 161:6970–6976

    PubMed  CAS  Google Scholar 

  35. Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn J-C (2000) Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis, J Immunol methods 244:59–67

    Article  PubMed  CAS  Google Scholar 

  36. Reynolds SR, Zeleniuch-Jacquotte A, Shapiro RL, Roses DF, Harris MN, Johnston D, Bystryn JC (2003) Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. Clin Cancer Res 9:657–662

    PubMed  CAS  Google Scholar 

  37. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915

    Article  PubMed  CAS  Google Scholar 

  38. Sato Y, Maeda Y, Shomura H, Sasatomi T, Takahashi M, Une Y, Kondo M, Shinohara T, Hida N, Katagiri K, Sato K, Sato M, Yamada A, Yamana H, Harada M, Itoh K, Todo S (2004) A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br J Cancer 90:1334–1342

    Article  PubMed  CAS  Google Scholar 

  39. Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH (2003) Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21:4016–4026

    Article  PubMed  CAS  Google Scholar 

  40. Speiser DE, Rimoldi D, Batard P, Lienard D, Lejeune F, Cerottini JC, Romero P (2003) Disease-driven T cell activation predicts immune responses to vaccination against melanoma. Cancer Immun 3:12

    PubMed  Google Scholar 

  41. Van Slooten ML, Storm G, Zoephel A, Kupcu Z, Boerman O, Crommelin DJ, Wagner E, Kircheis R (2001) Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines. Pharm Res 17:42–48

    Article  Google Scholar 

  42. Weinreich DM, Rosenberg SA (2002) Response rates of patients with metastatic melanoma to high dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2. J immunother 25:185–187

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hunter College School of Health Sciences, New York, NY, USA

    Dean Johnston

  2. Department of Dermatology and the NYU Cancer Institute, New York University Medical Center, New York, NY, USA

    Dean Johnston, Sandra R. Reynolds & Jean-Claude Bystryn

Authors
  1. Dean Johnston
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sandra R. Reynolds
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean-Claude Bystryn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dean Johnston.

Additional information

Supported by grant CA096804 (DJ)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johnston, D., Reynolds, S.R. & Bystryn, JC. Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice. Cancer Immunol Immunother 55, 412–419 (2006). https://doi.org/10.1007/s00262-005-0013-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-005-0013-x

Keywords

Search

Navigation